Home / Kexing Biopharm...

Kexing Biopharm Product Introduction-20251023

Article source：

Oct 22,2025

View： 943

LABEL:

Related News

Kexing Biopharm and Sinotherapeutics Reach Cooperation Agreement to Expand Overseas Markets for FDA-Approved Tofacitinib Product

Kexing Biopharm and Sinotherapeutics Reach Cooperation Agreement to Expand Overseas Markets for FDA-Approved Tofacitinib Product

Kexing Biopharm Announces First Patient Dosed in Phase I Clinical Trial of Ophthalmology Innovative Drug GB10

Kexing Biopharm Announces First Patient Dosed in Phase I Clinical Trial of Ophthalmology Innovative Drug GB10

Kexing Biopharm’s Innovative Drug GB19 Received Approval From FDA To Conduct Clinical Trials

Kexing Biopharm’s Innovative Drug GB19 Received Approval From FDA To Conduct Clinical Trials

Kexing Biopharm's innovative drug "GB19 Injection" received approval from NMPA to conduct clinical trials in China

Kexing Biopharm's innovative drug "GB19 Injection" received approval from NMPA to conduct clinical trials in China

Completion of PIC/S Participating Authorities' Audits of Kexing Biopharm's licensed Product Infliximab for Injection

Completion of PIC/S Participating Authorities' Audits of Kexing Biopharm's licensed Product Infliximab for Injection

Kexing Biopharm’s GB18 project received clearance of IND application from NMPA and FDA

Kexing Biopharm’s GB18 project received clearance of IND application from NMPA and FDA